Orchard Therapeutics plc (NASDAQ:ORTX) does about 524.33K shares in volume on a normal day but saw 16670425 shares change hands in Tuesday trading. The company now has a market cap of 598.47M USD. Its current market price is $6.12, marking an increase of 10.67% compared to the previous close of $5.53. The 52 week high reached by this stock is $17.48 whilst the lowest price level in 52 weeks is $4.44. The script in recent trading has seen the stock touch a high of $7.35 and a low of $5.92.
Orchard Therapeutics plc (ORTX) has a 20-day trading average at $4.94 and the current price is -64.99% off the 52-week high compared with 37.84% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.49 and its 200-day simple moving average is $9.67. If we look at the stock’s price movements over the week, volatility stands at 13.24%, which decreases to 8.02% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 70.71 to suggest the stock is overbought.
7 analysts observing the Orchard Therapeutics plc (ORTX) stock have set the 12-month price targets for the company’s shares at between $9.00 and $26.00. The median price target is 59.2% away from the current levels at $15.00.
FactSet Research has provided data showing that 7 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 7 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 01, 2020 when Oppenheimer resumed the stock to “Outperform” and issued a price target of.
The current price level is 25.04%, 10.87%, and -36.95% away from its SMA20, SMA50, and SMA200 respectively, with the ORTX price moving below the 50-day SMA on August 25. Orchard Therapeutics plc (ORTX) stock is up 27.50% over the week and 17.02% over the past month. Its price is -55.49% year-to-date and -55.72% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.48 below consensus estimates by -$0.06. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$0.45 and -$1.88 for whole year. ORTX’s earnings per share are forecast to shrink by -7.40% this year and 5.30% over next year. Expected sales for next quarter are $280k, which analysts say will come at $1.19 million for the current fiscal year and next year at $7.46 million. In addition, estimates put the company’s current quarterly revenue at an average of $280k.
Its 12-month price target is $15.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $9.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $26.00.
Outstanding shares total 99.25M with insiders holding 13.46% of the shares and institutional holders owning 73.71% of the company’s common stock. The company has a return on investment of -52.70% and return on equity of -63.80%. Price to book ratio is 2.67 and price to sales ratio is 193.06.
According to a U.S. Securities and Exchange Commission filing, Federated Hermes Kaufmann Small C has added its position in Orchard Therapeutics plc (ORTX) to 2,431,502 shares, mirroring a recent increase by 21.58%. Federated Hermes Kaufmann Small C added 0.43 million shares of Orchard Therapeutics plc common stock bringing its total worth to about $12.5 million at the end of recent close, SEC documents show. Federated Hermes Kaufmann Small C isn’t the only investment manager who changed stakes and is followed by T Rowe Price New Horizons Fund, which added 0.59 million shares to end up with 1,638,943 shares worth $8.42 million. Artisan Small Cap Fund raise their holdings by 21.40% in the company over the course of the most recent quarter. It now holds a 1.67% position in Orchard Therapeutics plc thanks to 1.63 million shares amounting to $8.36 million.